Suivre
Abonner AmVac AG

AmVac AG

Filtre
  • 13.03.2015 – 11:21

    AmVac AG strengthens management / Ali Pashazadeh appointed CEO effective immediately

    Zug (ots) - The Board of Directors of AmVac AG has appointed Ali Pashazadeh with immediate effect as Chief Executive Officer of the Zug based life science company focused on innovative vaccines. After transferring her operating management responsibilities to Ali Pashazadeh, company founder Melinda Karpati will focus on chairing the Scientific Committee of the AmVac ...

  • 19.12.2014 – 09:01

    New possibilities in the fight against pancreatic cancer

    Zug, Switzerland (ots) - Licence extension in the contract between AmVac and the Helmholtz Centre for the adjuvant Malp-2 offers sustainable potential for patients, attending physicians and for pharmaceutical and medical research. Milestone thanks to licence extension The licence for Malp-2 was successfully extended in November 2014. The adjuvant can now be used for the first time for all preventive and therapeutic ...

  • 20.06.2013 – 13:48

    AmVac Receives Two EU Grants for the Development of Novel Vaccines

    Zug (ots) - AmVac AG announces today that the EU has approved two grant applications under the seventh framework programme (FP7) for the development of innovative vaccines against flu and leishmaniasis. The projects are joint initiatives of AmVac, other European companies and research institutes with leading expertise in vaccine design and development. Total funding for all participating partners is approximately EUR 6 ...

  • 07.03.2013 – 08:00

    AmVac's Vaccine against RSV Attains Next Milestone

    Zug (ots) - AmVac AG announces new preclinical data on its vaccine candidate AMV602 for the prevention of infections caused by respiratory syncytial virus (RSV). Last fall, the company selected the candidate as the most promising for further development among a range of potential leads. In preclinical studies, renowned RSV expert Prof.ssa Grazia Cusi and her team at the University of Siena, Italy, have now confirmed the ...

  • 03.03.2010 – 12:42

    AmVac AG registers progress with the RSV vaccine

    Zug (ots) - The Swiss AmVac AG, a biopharmaceutical company located in Zug, has made significant advances in the manufacture and production of its vaccine candidate against RSV over the last few months. This vaccine candidate is based on the new Sendai vector technology for which Max-Planck-Innovations GmbH has acquired the exclusive licence. This technology, which has been developed by Prof. Wolfgang Neubert's ...

  • 03.12.2009 – 09:54

    V+ invests in AmVac AG

    Zug (ots) - The Swiss biopharmaceuticals company AmVac AG in Zug has joined forces with the long-term strategic investor V+ GmbH & Co Fonds 2 KG. The private equity company based in Dresden has invested CHF 1,500,000 in AmVac AG since the first half of 2009. Last week V+ GmbH & Co Fonds 2 KG announced their intention of acquiring further shares in AmVac AG to the sum of CHF 3,000,000.00. Michael Vogel, spokesman of the investment board: "We agree with boosting ...

  • 14.07.2008 – 14:25

    AmVac AG Expands Its Advisory Board with Hartmut Retzlaff, CEO of STADA Arzneimittel AG

    Zug (ots) - The Swiss company AmVac AG, a biopharmaceutical company based in Zug, has announced the expansion of its Advisory Board. With the acquisition of Hartmut Retzlaff, CEO of STADA Arzneimittel AG, AmVac now has one of the most successful company managers in the German pharmaceutical industry on the Board. Hartmut Retzlaff has been head of STADA AG since 1994 ...

  • 12.06.2008 – 08:50

    AmVac AG Begins Research Cooperation with Bayer

    Zug, Catania (ots) - AmVac AG, a Swiss biopharmaceutical company based in Zug, is starting its first research cooperation program with Bayer Innovation GmbH on the development of a new influenza vaccine. Joint research and development work is beginning with the Bayer subsidiary Icon Genetics GmbH on a novel production approach. Antigens are to be produced for the first time in tobacco plants which along with AmVac AG's ...

  • 21.12.2007 – 16:50

    Dr. Wolfgang Schmidt appointed AmVac AG COO

    Zug (ots) - AmVac AG has a new executive officer on board - Dr. Wolfgang Schmidt agreed to join the company in early December to lead its operational business. Dr. Wolfgang Schmidt is a graduated chemist who began his career with Hoechst AG in Frankfurt/Main, Germany. After a variety of stints in pharmaceutical research, he directed the site-management Frankfurt department in the lead generation research segment. ...

  • 07.09.2007 – 14:42

    Ariane Meynert Joins Swiss AmVac AG

    Zug (ots) - As of September 1, 2007 Ariane Meynert is joining Swiss biotech company AmVac AG, Zug, as Managing Director in charge of investor and public relations. Management graduate Meynert comes from TOMORROW FOCUS AG in Munich, a Hubert Burda Medien AG Group company where she was in charge of developing investor and public relations for several years. She previously supervised, in the same function, the ...